Trials / Unknown
UnknownNCT01852409
Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites
Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Malignant ascites often has a profound impact on the quality of life of cancer patients. Current treatments,including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab for the palliation of malignant ascites might be a novel choice for refractory malignant ascites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2013-05-13
- Last updated
- 2013-05-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01852409. Inclusion in this directory is not an endorsement.